Trending Now
Mustang Bio Inc. (NASDAQ:MBIO) Receives Orphan Drug Designation For MB-207 in...
Mustang Bio Inc. (NASDAQ:MBIO) has been awarded Orphan Drug Designation for MB-207, its lentiviral gene therapy for treating patients with X-linked severe combined immunodeficiency...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Receives GMP Approval For COVISTIX From...
Sorrento Therapeutics Inc. (NASDAQ: SRNE) has received approval for COVISTIX from the Brazilian regulatory agency (ANVISA). COVISTIX is a diagnostic tool that has the...
MAKE IT MODERN
LATEST REVIEWS
iBio Inc.’s (NYSE: IBIO) Full Year 2021 Revenue Grew 50% to...
iBio Inc. (NYSE: IBIO) has announced its Q4 and full-year 2021 financial results and provided a business update.
iBio reported full-year revenue of $2.4 million
The...
MAKE IT MODERN
PERFORMANCE TRAINING
Assembly Biosciences Inc. (NASDAQ: ASMB) Discontinues ABI-H2158 Development Following Elevated ALT Levels
Assembly Biosciences Inc. (NASDAQ: ASMB) has announced that it will discontinue ABI-H2158 (2158) development t after observing elevated ALT levels consistent with treatment-induced hepatoxicity...
Altimmune Inc. (NASDAQ:ALT) Submits Investigational New Drug Application for AdCOVID™ COVID-19 Vaccines
Altimmune Inc. (NASDAQ:ALT) has submitted an Investigational New Drug (IND) application to the FDA for the commencement of Phase 1 clinical study...
Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA
Chimerix Inc (NASDAQ: CMRX) has received a $25.3 million contract agreement from the Public Health Agency of Canada for the procurement of TEMBEX (brincidofovir)....
CytomX Therapeutics Inc. (NASDAQ: CTMX) Reports Interim Results For Phase 2 Study HNSCC and...
CytomX Therapeutics Inc. (NASDAQ: CTMX) has announced interim results of the second phase study in patients with head and neck squamous cell carcinoma and...
Trading SPY during the Santa Rally
The market continues to melt higher but with low volume this week. Not necessarily in a way that is has been helpful...
MAKE IT MODERN
